Trial data show daraxonrasib extended survival in previously treated metastatic pancreatic cancer
The Facts
- A clinical trial found that daraxonrasib improved survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer.
- Multiple reports said the trial included 500 patients.
- Reported average survival was 13.2 months for patients receiving daraxonrasib versus 6.6 months for patients receiving chemotherapy.
- Daraxonrasib was reported as a once-daily oral pill in the trial.
- Several reports said daraxonrasib caused fewer severe side effects than chemotherapy.
- The trial results were presented at the American Society of Clinical Oncology meeting in Chicago and were published in The New England Journal of Medicine.
- Reports said daraxonrasib targets KRAS-related tumor growth, and KRAS mutations are found in more than 90% of pancreatic cancers.
- The drug is still experimental, and at least one report said it has been fast-tracked by the U.S. Food and Drug Administration for approval.
How left and right are reading this
- Both agree
- An experimental once-daily pill beat chemotherapy in previously treated metastatic pancreatic cancer on both survival and severe side effects, a result serious enough to suggest KRAS-targeted treatment may offer a more effective, more tolerable path than standard care.
- They split on
- Less a disagreement than a question of emphasis: a more tolerable, more precisely targeted direction for care versus the strength and credibility of a 500-patient result presented at ASCO and published in The New England Journal of Medicine.
Analytical frames for this storyTap to explore
Context
Who were the patients in this trial?
The study involved patients with metastatic pancreatic cancer whose disease had already been treated and was no longer responding to prior chemotherapy; reports also describe the trial as enrolling 500 patients across North America, Europe and Asia BBC,India Today,Yahoo! Finance.
How does daraxonrasib work?
Reports say daraxonrasib blocks KRAS-driven tumor growth. That matters because KRAS mutations are found in more than 90% of pancreatic tumors, making it a widely relevant target in this cancer Yahoo! Finance,Independent,CBS News.
View all 95 sources
Wire services (4)
Independent coverage (50)
N-tvWirkstoff erzielt "Durchbruch": Studie: Überlebenszeit bei g...
wallstreet:onlineImmuneering Presents Compelling 17.3-Month Median Overall Su...
India TodayNew pill becomes game changer for pancreatic cancer, doubles...
ProPakistaniNew Pill Doubles Survival Time Among Advanced Pancreatic Can...
Sözcü GazetesiBu hap pankreas kanseri hastalarına umut oldu: Ömürleri iki ...
MorningstarDoctors stood up and cheered mid-presentation for this histo...
Herald Sun'Absolutely phenomenal': Single pill offers hope against dea...
LaSextaIdentifican un tratamiento que duplica la supervivencia en c...
MorningstarWhy doctors stood up and cheered mid-presentation for a hist...
Franceinfo"Une vague de biotechnologies porteuse d'espoir" : les nouve...
Express.co.ukBreakthrough against 'most-feared' cancer hailed by doctors ...
LADbibleNew daily pill can double survival time for world's deadlies...
DikenYeni deneysel ilaç: Pankreas kanserinde yaşam süresini uzatı...
TürkiyePankreas kanseri hastalarına müjde! Yeni geliştirilen ilaç, ...
Anadolu AjansıAraştırmaya göre, yeni deneysel ilaç bazı pankreas kanseri t...
HaberlerAraştırmaya göre, yeni deneysel ilaç bazı pankreas kanseri t...
FanpageTumore al pancreas, pillola daraxonrasib raddoppia la soprav...
FranceinfoCancer du pancréas : "On a ouvert une porte" avec ce nouveau...
TodaySvolta sul tumore al pancreas: la nuova pillola raddoppia la...
ITV HubNew pill helps double survival time for people with advanced...
KCRAExperimental pill promises new hope for deadly pancreatic ca...
BBCDaily pill daraxonrasib doubles survival time for pancreatic...
The Times of IndiaExperimental pill promises new hope for deadly pancreatic ca...
www.theepochtimes.comUCLA-Led Study Finds New Pancreatic Cancer Drug 'Significant...
MyJoyOnline.comDaily pill doubles survival time for pancreatic cancer patie...
Lenta.ruСтало известно об успешных испытаниях новой вакцины против р...
Беларускае тэлеграфнае агенцтваЭкспериментальная вакцина от рака в США вызвала улучшение у ...
ФедералПресс"Огромный шаг вперед": ученые заявили о прорыве в лечении ра...
Пятый канал - Главные новости России и мира сегодняThe Guardian сообщила об успешных испытаниях новой вакцины о...
La NacionCumbre anual de oncólogos: tres desafíos que persisten para ...
Izvestia.ruThe Guardian сообщила об успешных испытаниях новой вакцины п...
РИА НовостиЭкспериментальная вакцина от рака в США вызвала улучшение у ...
Corriere della SeraTumore del pancreas, un nuovo farmaco rivoluziona le cure
Radio SarajevoNova terapija protiv raka dala neviđene rezultate: "Ovaj tre...
Аргументы и фактыНовая вакцина против рака уничтожила опухоли у 15 тяжелоболь...
kp.ruGuardian: Экспериментальная вакцина от рака уничтожила опухо...
Life.ruThe Guardian: Новая вакцина уничтожила опухоли у пациентов с...
Московский КомсомолецThe Guardian: экспериментальная вакцина от рака уничтожила о...
vesti.ruВрачи рассказали об убивающей раковые опухоли онковакцине - ...
NewserPancreatic Cancer Trial Shows Pill Doubling Survival Rates
inews.co.ukWhy this new pill for a deadly cancer has doctors excited
Primera HoraPíldora experimental promete nueva esperanza contra el cánce...
ANSA.itEsperto, 'per pazienti con tumore al pancreas si apre un nuo...
Вечерняя МоскваThe Guardian: Экспериментальная вакцина уничтожила опухоли у...
20 minutosUn ensayo identifica un tratamiento que duplica la supervive...
La Presse.caLutte contre le cancer du pancréas | Un médicament offre un ...
NBC ChicagoAfter new drug's 'unprecedented' results for pancreatic canc...
VestiПрорыв в лечении рака? Новый препарат излечил более 40 проце...
TelemundoUna pastilla experimental ofrece esperanza ante el cáncer de...
Cadena SERUna pastilla al día podría aumentar el doble la esperanza de...
About these frames
The First Responder: Who gets hurt or helped. Quality of life, vulnerable groups, public health, human cost and benefit.
The Architect: Stability, law, enforcement, institutional design, separation of powers, regulatory process, rule of law. How are order and governance maintained?
The Analyst: Costs, jobs, inflation, growth, incentives, markets, tradeoffs. Follow the money.
See this differently than someone you know would? Two ways to keep it going.
The dial works on any URL — paste an article you read elsewhere this week.